Table of Content


List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Viral Conjunctivitis - Overview
Viral Conjunctivitis - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Products under Development by Companies
Viral Conjunctivitis - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Viral Conjunctivitis - Companies Involved in Therapeutics Development
Adenovir Pharma AB
Invirsa Inc
IVIEW Therapeutics Inc
noViricides Inc
Okogen Inc
Panoptes Pharma GesmbH
Starpharma Holdings Ltd
TGV-Inhalonix Inc
Viral Conjunctivitis - Drug Profiles
APD-209 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
APD-514 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
astodrimer - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
EKCCide-I - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
INV-102 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Mul-1867 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
povidone iodine ER - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
PP-001 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ranpirse - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Viral Conjunctivitis - Dormant Projects
Viral Conjunctivitis - Discontinued Products
Viral Conjunctivitis - Product Development Milestones
Featured News & Press Releases
Dec 20, 2019: iView announces first patient treated in phase 2 clinical trial program evaluating IVIEW-1201 in patients with acute adenoviral conjunctivitis
Dec 27, 2018: US FDA requests further data for VivaGel BV approval
Dec 12, 2018: US patent granted for SPL7013 eye drops for conjunctivitis
Mar 06, 2017: iVIEW Therapeutics will present its novel sustained-release povidone iodine ophthalmic formulation for the treatment of acute conjunctivitis in TechConnect World Innovation Summit & Expo and US tiol Innovation Summit and tiol SBIR/STTR Conference
Sep 12, 2016: iVIEW Therapeutics was awarded SBIR Innovative grant by NIH’s tiol Eye Institute
May 13, 2013: Starpharma’s Dendrimer SPL7013 Demonstrates Potential As Viral Conjunctivitis Treatment
Oct 11, 2012: Adenovir Pharma Announces Completion Of Phase I Study Of APD -209 To Treat Epidemic Keratoconjunctivitis
Aug 22, 2011: Researchers Discover New Drug To Treat Epidemic Keratoconjuntivitis
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer



List of Figures


Number of Products under Development for Viral Conjunctivitis, H1 2020
Number of Products under Development by Companies, H1 2020
Number of Products by Targets, H1 2020
Number of Products by Stage and Targets, H1 2020
Number of Products by Mechanism of Actions, H1 2020
Number of Products by Stage and Mechanism of Actions, H1 2020
Number of Products by Routes of Administration, H1 2020
Number of Products by Stage and Routes of Administration, H1 2020
Number of Products by Molecule Types, H1 2020
Number of Products by Stage and Molecule Types, H1 2020


List of Tables


Number of Products under Development for Viral Conjunctivitis, H1 2020
Number of Products under Development by Companies, H1 2020
Products under Development by Companies, H1 2020
Number of Products by Stage and Target, H1 2020
Number of Products by Stage and Mechanism of Action, H1 2020
Number of Products by Stage and Route of Administration, H1 2020
Number of Products by Stage and Molecule Type, H1 2020
Viral Conjunctivitis - Pipeline by Adenovir Pharma AB, H1 2020
Viral Conjunctivitis - Pipeline by Invirsa Inc, H1 2020
Viral Conjunctivitis - Pipeline by IVIEW Therapeutics Inc, H1 2020
Viral Conjunctivitis - Pipeline by NanoViricides Inc, H1 2020
Viral Conjunctivitis - Pipeline by Okogen Inc, H1 2020
Viral Conjunctivitis - Pipeline by Panoptes Pharma GesmbH, H1 2020
Viral Conjunctivitis - Pipeline by Starpharma Holdings Ltd, H1 2020
Viral Conjunctivitis - Pipeline by TGV-Inhalonix Inc, H1 2020
Viral Conjunctivitis - Dormant Projects, H1 2020
Viral Conjunctivitis - Discontinued Products, H1 2020